BeOne Medicines (ONC) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on BeOne Medicines (ONC) is Neutral.

The composite score behind that read is +0.08, weighing +0.13 of bullish evidence against -0.22 bearish.

BeOne Medicines last closed at $361.65, +1.00% on the session.

Against the IVW growth benchmark the position is +0.08% over the forecast window.

The read is built from 12 underlying insights — 10 bullish and 2 bearish.

Agreement across those insights is 75%.

8 graded predictions for ONC so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks BeOne Medicines in the 11th percentile on valuation and the 71st percentile on return on equity, where 100 is best.

BeOne Medicines is classified under Health Care / Biotechnology, with a market capitalisation of $39.31B.

StockMap tracks BeOne Medicines as the 10th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite BeOne Medicines ranks 18th of 344 in the group, against a group median of -0.21.